3. Vitamin D preparations versus placebo/no treatment.
| Outcomes | Eke 1983 | Greenbaum 2005 | Greenbaum 2007 | Watson 1988 | Summary estimatea |
| Number with abnormal bone histology | 7/8b versus 2/7c | Not reported | Not reported | Reduced osteoid, bone formation and resorption in 1αOHD versus control | RR 0.17 (0.03 to 1.16) |
| PTH (pmol/L) | No difference | Not reported | Not reported | 18 ± 15 versus 73 ± 32 | MD ‐55.00 (‐83.03 to ‐26.97) |
| Elevated PTH | Not reported | Not reported | Not reported | 1/6 versus 6/6 | RR 0.17 (0.03 to 1.00) |
| Number with 30% fall in PTH | Not reported | 11/21 versus 5/26 | 9/15 versus 3/14 | Not reported | RR 2.75 (1.39 to 5.47) |
| Change in PTH (pg/mL) | Not reported | ‐193 ± 637 versus 10 ± 347 | ‐164 versus +238 | Not reported | MD ‐203.00 (‐506.34 to 100.34) |
| Hypercalcaemic patients | 0/8 versus 0/7 | 5/21 versus 0/26 | 0/15 versus 0/14 | 3/6 versus 2/6 | RD 0.08 (‐0.08 to 0.24) |
| Ca x P > 7.5 mg2/dL2 | Not reported | 8/21 versus 1/26 | Not reported | Not reported | RD 0.34 (0.12 to 0.56) |
| Phosphorus > 6.5 mg/dL x 2 | Not reported | 15/21 versus 12/26 | Not reported | Not reported | RD 0.25 (‐0.02 to 0.52) |
| Change in serum calcium (mg/dL) | No difference | 0.38 ± 0.6 versus 0.08 ± 0.66 | 0.00 ± 1.01 versus 0.29 ± 1.01 | No difference | MD ‐0.10 (‐0.45 to 0.65) |
| Change in Ca x P (mg2/dL2) | Not reported | 4.7 ± 12.4 versus 0.6 ± 14.8 | ‐1.35 ± 14.1 versus 3.21 ± 14.1 | Not reported | MD ‐0.45 (‐7.94 to 8.83) |
| Change in serum phosphorus (mg/dL) | No difference | 0.23 ± 1.33 versus 0.00 ± 1.68 | ‐0.15 ± 1.35 versus 0.18 ± 1.35 | No difference | MD ‐0.01 (‐0.66 to 0.63) |
| Change in bone ALP (U/L) | No difference | ‐4.5 ± 67 versus 43.2 ± 66 | Not reported | Not reported | MD ‐47.70 (‐88.54 to ‐6.86) |
a Summary estimate (RR, RD, MD) and 95% CI
b Experimental intervention
c Comparative intervention
ALP ‐ alkaline phosphatase; Ca x P ‐ calcium‐phosphorus product; PTH ‐ parathyroid hormone